<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Landing Page Article</title>
    <!-- BS CSS Stylesheet -->
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.1/dist/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-4bw+/aepP/YC94hEpVNVgiZdgIC5+VKNBQNGCHeKRQN+PtmoHDEXuppvnDJzQIu9" crossorigin="anonymous">
    <link rel="stylesheet" href="style.css">
    <!-- BS JS Stylesheet -->
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.2/dist/js/bootstrap.bundle.min.js" integrity="sha384-MrcW6ZMFYlzcLA8Nl+NtUVF0sA7MsXsP1UyJoMp4YLEuNSfAP+JcXn/tWtIaxVXM" crossorigin="anonymous" defer></script>

</head>

<body>
    <nav class="navbar navbar-expand-lg bg-dark">
        <div class="container navbar-dark">
            <a href="index.html" class="navbar-brand"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" fill="currentColor" class="bi bi-virus" viewBox="0 0 16 16">
                    <path d="M8 0a1 1 0 0 1 1 1v1.402c0 .511.677.693.933.25l.7-1.214a1 1 0 0 1 1.733 1l-.701 1.214c-.256.443.24.939.683.683l1.214-.701a1 1 0 0 1 1 1.732l-1.214.701c-.443.256-.262.933.25.933H15a1 1 0 1 1 0 2h-1.402c-.512 0-.693.677-.25.933l1.214.701a1 1 0 1 1-1 1.732l-1.214-.7c-.443-.257-.939.24-.683.682l.701 1.214a1 1 0 1 1-1.732 1l-.701-1.214c-.256-.443-.933-.262-.933.25V15a1 1 0 1 1-2 0v-1.402c0-.512-.677-.693-.933-.25l-.701 1.214a1 1 0 0 1-1.732-1l.7-1.214c.257-.443-.24-.939-.682-.683l-1.214.701a1 1 0 1 1-1-1.732l1.214-.701c.443-.256.261-.933-.25-.933H1a1 1 0 1 1 0-2h1.402c.511 0 .693-.677.25-.933l-1.214-.701a1 1 0 1 1 1-1.732l1.214.701c.443.256.939-.24.683-.683l-.701-1.214a1 1 0 0 1 1.732-1l.701 1.214c.256.443.933.261.933-.25V1a1 1 0 0 1 1-1Zm2 5a1 1 0 1 0-2 0 1 1 0 0 0 2 0ZM6 7a1 1 0 1 0-2 0 1 1 0 0 0 2 0Zm1 4a1 1 0 1 0 0-2 1 1 0 0 0 0 2Zm5-3a1 1 0 1 0-2 0 1 1 0 0 0 2 0Z" />
                </svg></a>
            <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#nav2">
                <div class="navbar-toggler-icon"></div>
            </button>
            <div class="collapse navbar-collapse" id="nav2">
                <ul class="navbar-nav">
                    <li class="nav-item">
                        <a href="index.html" class="nav-link">HEPION</a>
                    </li>
                    <li class="nav-item">
                        <a href="about.html" class="nav-link">RENCOFILSTAT</a>
                    </li>
                    <li class="nav-item">
                        <a href="article.html" class="nav-link">NASH ARTICLES</a>
                    </li>
                    <li class="nav-item">
                        <a href="landscape.html" class="nav-link active">NASH LANDSCAPE</a>
                    </li>
                    <li class="nav-item">
                        <a href="result.html" class="nav-link">NASH RESULT</a>
                    </li>
                </ul>
            </div>
        </div>
    </nav>
    <div class="container my-5 mx-auto px-0 shadow-lg">
        <table class="table table-striped table-primary">
            <thead>
                <tr class="table-dark">
                    <th scope="col">DRUG NAME</th>
                    <th scope="col">COMPANY</th>
                    <th scope="col">TYPE</th>
                    <th scope="col">Market Cap</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Pegozafermin</td>
                    <td>89bio</td>
                    <td>THR-β</td>
                    <td>1.29B</td>
                </tr>
                <tr>
                    <td>Efruxiferimin</td>
                    <td>Akero </td>
                    <td>FGF21</td>
                    <td>2.76B</td>
                </tr>
                <tr>
                    <td>Pemvidutide</td>
                    <td>Altimmune</td>
                    <td>GLP-1</td>
                    <td>133.3M</td>
                </tr>
                <tr>
                    <td>Rencofilstat</td>
                    <td>Hepion</td>
                    <td>Cyclophilin</td>
                    <td>28.6M</td>
                </tr>
                <tr class="table-danger">
                    <td class="cancel">Obeticholic</td>
                    <td>Intercept</td>
                    <td>FXR</td>
                    <td>452.5M</td>
                </tr>
                <tr>
                    <td>Lanifibranor</td>
                    <td>Inventiva</td>
                    <td>PPAR</td>
                    <td>146.4M</td>
                </tr>
                <tr>
                    <td>Resmetirom</td>
                    <td>Madrigal</td>
                    <td>THR-β</td>
                    <td>3.32B</td>
                </tr>
                <tr>
                    <td>Aldafermin</td>
                    <td>NGM Bio</td>
                    <td>FGF19</td>
                    <td>156.6M</td>
                </tr>
                <tr>
                    <td>Semaglutide</td>
                    <td>Novo Nordisk</td>
                    <td>GLP-1R</td>
                    <td>318.7B</td>
                </tr>
                <tr>
                    <td>TERN-501</td>
                    <td>Terns</td>
                    <td>THR-β</td>
                    <td>321.8M</td>
                </tr>
                <tr>
                    <td>VK2809</td>
                    <td>Viking </td>
                    <td>FGF21</td>
                    <td>1.38B</td>
                </tr>
                <!-- CODE DIVISON -->
                <tr class="table-dark text-center">
                    <td colspan="4" class="">Other Potential NAFLD/NASH</td>
                </tr>
                <tr>
                    <td></td>
                    <td>AbbVie</td>
                    <td></td>
                    <td>259.3B</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Aligos</td>
                    <td></td>
                    <td>37.2M</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Amgen</td>
                    <td></td>
                    <td>137.1B</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Arrowhead</td>
                    <td></td>
                    <td>2.96B</td>
                </tr>
                <tr>
                    <td></td>
                    <td>AstraZeneca</td>
                    <td></td>
                    <td>207B</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Axcella Health</td>
                    <td></td>
                    <td>17M</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Boehringer Ingelheim</td>
                    <td></td>
                    <td>191.4B</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Boston</td>
                    <td></td>
                    <td>78.98B</td>
                </tr>
                <tr>
                    <td>BMS-986263</td>
                    <td>Bristol-Myers Squibb</td>
                    <td>HSP47</td>
                    <td>128.7B</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Elgia</td>
                    <td></td>
                    <td>220.1M</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Eli Lilly</td>
                    <td></td>
                    <td>526.1B</td>
                </tr>
                <tr>
                    <td></td>
                    <td>ENYO</td>
                    <td></td>
                    <td>Private</td>
                </tr>
                <tr>
                    <td>Belapectin</td>
                    <td>Galectin</td>
                    <td>Gal-3</td>
                    <td>104.2M</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Galecto</td>
                    <td></td>
                    <td>16.4M</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Galmed</td>
                    <td></td>
                    <td>3.08M</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Genentech</td>
                    <td></td>
                    <td>Private</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Genfit</td>
                    <td></td>
                    <td>177.6M</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Gilead</td>
                    <td></td>
                    <td>95.3B</td>
                </tr>
                <tr>
                    <td></td>
                    <td>GSK</td>
                    <td></td>
                    <td>71.6B</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Hepatx</td>
                    <td></td>
                    <td>Private</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Hightide</td>
                    <td></td>
                    <td>145.6M</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Histogen</td>
                    <td></td>
                    <td>2.89M</td>
                </tr>
                <tr>
                    <td></td>
                    <td>J&J</td>
                    <td></td>
                    <td>389.3B</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Life BioScience</td>
                    <td></td>
                    <td>Private</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Lipocine</td>
                    <td></td>
                    <td>21M</td>
                </tr>
                <tr>
                    <td>MN-001</td>
                    <td>Medicinova</td>
                    <td>Multi-Target</td>
                    <td>119.6M</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Merck & Co</td>
                    <td></td>
                    <td>276.5B</td>
                </tr>
                <tr>
                    <td></td>
                    <td>NeuroBo</td>
                    <td></td>
                    <td>17.1M</td>
                </tr>
                <tr>
                    <td>Secukinumab</td>
                    <td>Novartis</td>
                    <td>Antibody</td>
                    <td>229.9B</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Pfizer</td>
                    <td></td>
                    <td>199.7B</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Sagimet</td>
                    <td></td>
                    <td>257.9M</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Salix</td>
                    <td></td>
                    <td>Private</td>
                </tr>
                <tr>
                    <td></td>
                    <td>Viscient</td>
                    <td></td>
                    <td>Private</td>
                </tr>
            </tbody>
        </table>
    </div>    

    <footer class="py-3 mt-5 mb-3">
        <ul class="nav justify-content-center border-bottom pb-3 mb-3">
          <li class="nav-item"><a href="index.html" class="nav-link px-2 text-body-secondary">Hepion</a></li>
          <li class="nav-item"><a href="about.html" class="nav-link px-2 text-body-secondary">CRV431</a></li>
          <li class="nav-item"><a href="article.html" class="nav-link px-2 text-body-secondary">Article</a></li>
          <li class="nav-item"><a href="landscape.html" class="nav-link px-2 text-body-secondary">Landscape</a></li>
          <li class="nav-item"><a href="result.html" class="nav-link px-2 text-body-secondary">Data</a></li>
        </ul>
        <p class="text-center text-body-secondary">© 2023 CapriceYuri</p>
      </footer>
</body>

</html>